GERN
Price
$1.61
Change
-$0.11 (-6.36%)
Updated
Mar 10, 04:59 PM (EDT)
Capitalization
1.1B
62 days until earnings call
SER
Price
$4.80
Change
-$0.00 (-0.00%)
Updated
Mar 10, 04:56 PM (EDT)
Capitalization
47.48M
Ad is loading...

GERN vs SER

Header iconGERN vs SER Comparison
Open Charts GERN vs SERBanner chart's image
Geron
Price$1.61
Change-$0.11 (-6.36%)
Volume$207.73K
Capitalization1.1B
Serina Therapeutics
Price$4.80
Change-$0.00 (-0.00%)
Volume$167
Capitalization47.48M
GERN vs SER Comparison Chart
Loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GERN vs. SER commentary
Mar 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and SER is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 11, 2025
Stock price -- (GERN: $1.73 vs. SER: $4.80)
Brand notoriety: GERN and SER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 96% vs. SER: 45%
Market capitalization -- GERN: $1.1B vs. SER: $47.48M
GERN [@Biotechnology] is valued at $1.1B. SER’s [@Biotechnology] market capitalization is $47.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $383.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whileSER’s FA Score has 1 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • SER’s FA Score: 1 green, 4 red.
According to our system of comparison, SER is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 4 TA indicator(s) are bullish.

  • GERN’s TA Score: 4 bullish, 3 bearish.

Price Growth

GERN (@Biotechnology) experienced а -1.70% price change this week, while SER (@Biotechnology) price change was -3.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.84%. For the same industry, the average monthly price growth was -7.68%, and the average quarterly price growth was -7.37%.

Reported Earning Dates

GERN is expected to report earnings on May 12, 2025.

SER is expected to report earnings on Mar 31, 2023.

Industries' Descriptions

@Biotechnology (+0.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($1.1B) has a higher market cap than SER($47.5M). SER YTD gains are higher at: -4.192 vs. GERN (-51.130). GERN has more cash in the bank: 340M vs. SER (3.19M). SER has less debt than GERN: SER (11.5M) vs GERN (87.3M).
GERNSERGERN / SER
Capitalization1.1B47.5M2,320%
EBITDA-187.93MN/A-
Gain YTD-51.130-4.1921,220%
P/E RatioN/A30.22-
Revenue29.5MN/A-
Total Cash340M3.19M10,675%
Total Debt87.3M11.5M759%
FUNDAMENTALS RATINGS
GERN vs SER: Fundamental Ratings
GERN
SER
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
9534
P/E GROWTH RATING
1..100
7319
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SER's Valuation (65) in the null industry is in the same range as GERN (92) in the Biotechnology industry. This means that SER’s stock grew similarly to GERN’s over the last 12 months.

GERN's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that GERN’s stock grew similarly to SER’s over the last 12 months.

GERN's SMR Rating (95) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that GERN’s stock grew similarly to SER’s over the last 12 months.

SER's Price Growth Rating (34) in the null industry is somewhat better than the same rating for GERN (95) in the Biotechnology industry. This means that SER’s stock grew somewhat faster than GERN’s over the last 12 months.

SER's P/E Growth Rating (19) in the null industry is somewhat better than the same rating for GERN (73) in the Biotechnology industry. This means that SER’s stock grew somewhat faster than GERN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERN
RSI
ODDS (%)
Bullish Trend 4 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
69%
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
82%
Aroon
ODDS (%)
Bearish Trend 4 days ago
76%
View a ticker or compare two or three
Ad is loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRVNX13.070.13
+1.00%
Mirova International Sustainable Eq N
IIGIX11.180.10
+0.90%
Voya Multi-Manager International Eq I
JEPCX14.480.08
+0.56%
JPMorgan Equity Premium Income C
JIVAX30.330.16
+0.53%
JPMorgan U.S. Applied Data Sci Val A
GTMRX17.51-0.04
-0.23%
Goldman Sachs Small/Mid Cap Growth R

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
+0.58%
SER - GERN
63%
Loosely correlated
+2.13%
LIANY - GERN
53%
Loosely correlated
+3.41%
VCYT - GERN
44%
Loosely correlated
-1.51%
MIRM - GERN
39%
Loosely correlated
+0.09%
NRIX - GERN
37%
Loosely correlated
-1.35%
More